T24 Xenograft Model Service for Bladder Cancer

The T24 Xenograft Model Service for Bladder Cancer provides a robust, clinically relevant preclinical platform for evaluating novel therapeutics against muscle-invasive urothelial carcinoma. Alfa Cytology delivers end-to-end T24 xenograft model development, from cell-line authentication and inoculation to longitudinal tumor monitoring and histopathological endpoint analysis, enabling rapid, data-driven decision-making in your oncology pipeline.

Overview of T24 Xenograft Model for Bladder Cancer

The T24 cell line-derived xenograft model represents one of the most extensively characterized preclinical systems for muscle-invasive bladder cancer (MIBC). Established from a high-grade transitional cell carcinoma of the bladder, T24 xenografts reliably recapitulate key histopathological features of human MIBC, including papillary growth patterns, muscle-invasive potential, and aberrant signaling through the MAPK and PI3K-AKT pathways. In immunodeficient hosts, T24 tumors exhibit rapid, reproducible engraftment with take rates exceeding 90%, making this model particularly suitable for pharmacokinetic-pharmacodynamic studies and combination therapy screening.

Molecular profiling studies have confirmed that T24 xenografts retain the mutational landscape of the parental cell line, including activating HRAS mutations, TP53 alterations, and CDKN2A loss, which collectively mirror the genomic architecture observed in a significant subset of human bladder cancer patients. This genetic fidelity, combined with the model's responsiveness to standard-of-care agents such as cisplatin and gemcitabine, positions the T24 xenograft as a cornerstone for translational bladder cancer research and investigational drug development.

Figure 1. T24 and 5637 stable cells were generated by infectionof lentiviral vectors expressing control versus two KDM4A-specific shRNAs (C, #1 and #2). (Yang, Hailang, et al., 2025)

Cell Line Information: T24

The T24 cell line is a human bladder transitional cell carcinoma line originally derived from an 81-year-old female patient diagnosed with high-grade, muscle-invasive bladder cancer. It was established in the early 1970s and has since become one of the most widely utilized models in bladder cancer research. The cell line exhibits epithelial morphology and demonstrates anchorage-dependent growth in standard culture conditions. T24 cells are characterized by an activating mutation in HRAS (G12V), loss of CDKN2A, and alterations in TP53, making them genetically representative of the basal/squamous molecular subtype of muscle-invasive bladder cancer. The line is known for its high proliferative index and robust tumorigenicity in immunodeficient mouse strains, with documented engraftment in both subcutaneous and orthotopic implantation settings.

Our Services

Alfa Cytology specializes in the development and execution of T24 xenograft models tailored to your preclinical research objectives. Our integrated service platform encompasses cell-line expansion, quality-controlled inoculation, real-time tumor volumetrics, and comprehensive histopathological endpoint analysis, ensuring reproducible, publication-ready data for your bladder cancer therapeutic programs. With stringent quality assurance protocols and flexible study designs, we provide the scientific rigor and operational efficiency required to advance your compounds from early validation through IND-enabling studies.

Workflow of T24 Xenograft Model Construction

The construction of a T24 xenograft model follows a standardized, multi-phase workflow designed to ensure high engraftment rates, reproducible tumor growth kinetics, and reliable therapeutic response data. Each stage is executed under rigorous quality control to maintain the genetic and phenotypic integrity of the model throughout the study duration.

1. Cell Line Preparation and Authentication: T24 cells are revived from authenticated master stocks and expanded under standardized culture conditions. Identity is verified by STR profiling, and cultures are confirmed mycoplasma-negative prior to inoculation.
2. Host Selection and Acclimatization: Immunodeficient mice (BALB/c nude, NOD-SCID, or NSG) are quarantined and acclimatized for a minimum of 5--7 days. Health status is evaluated by body weight monitoring and clinical observation before enrollment.
3. Cell Harvesting and Quality Control: Exponentially growing T24 cells are harvested at 70--80% confluence, washed in sterile PBS, and resuspended in serum-free medium or Matrigel. Viability is assessed by trypan blue exclusion, with only cultures showing >95% viability accepted for inoculation.
4. Tumor Cell Inoculation: A standardized inoculum (typically 1x10^6 to 5x10^6 cells in 100--200 uL) is injected subcutaneously into the flank or orthotopically into the bladder wall, depending on study objectives. Injection sites are monitored for leakage and immediate adverse reactions.
5. Tumor Monitoring and Measurement: Tumor dimensions are measured by digital caliper every 2--3 days, and volumes are calculated using the modified ellipsoid formula (L x W^2 x 0.5). For advanced studies, bioluminescence imaging or ultrasound may be employed for non-invasive longitudinal tracking.
6. Treatment Administration (Optional): Once tumors reach the target volume (typically 100--200 mm^3), animals are randomized into treatment and vehicle-control groups. Test articles are administered according to the predefined dosing regimen, with body weight and clinical signs recorded concurrently.
7. Endpoint Analysis and Tissue Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC), molecular analysis (qPCR, Western blot), or pharmacokinetic profiling. All tissues are archived according to GLP-compatible standards.

Figure 2. T24 xenograft model construction workflow.

Case Study-T24 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology developed a subcutaneous T24 xenograft model to support the efficacy evaluation of a novel targeted therapeutic candidate. The study demonstrated robust tumor engraftment within 10 days post-inoculation, with consistent exponential growth kinetics and predictable response to reference chemotherapeutic agents. Comprehensive endpoint analysis included tumor volume regression curves, body weight trajectories, and histopathological characterization of tumor architecture and proliferation markers. Detailed quantitative results, including tumor growth inhibition rates, pharmacodynamic biomarker data, and histological scoring, are available upon request under confidentiality agreements. Please contact our scientific team to discuss how this validated model can be adapted to your specific compound and study design requirements.

Why Choose Alfa Cytology?

Alfa Cytology combines deep oncology expertise with operational excellence to deliver T24 xenograft models that meet the highest standards of preclinical research. Our differentiated capabilities ensure reliable, actionable data for your therapeutic development programs.

• Authenticated, mycoplasma-free T24 master cell banks with documented STR profiles and passage history.
• Standardized xenograft construction protocols yielding >90% engraftment rates and reproducible tumor growth curves.
• Flexible study designs accommodating subcutaneous, orthotopic, and metastatic model configurations.
• Integrated in vivo imaging capabilities (bioluminescence, ultrasound) for real-time, non-invasive tumor monitoring.
• Comprehensive endpoint analysis including histopathology, immunohistochemistry, and molecular profiling under GLP-compatible workflows.
• Dedicated project management with rapid study initiation timelines and transparent, milestone-based reporting.
• Strict adherence to IACUC and institutional animal welfare guidelines, ensuring ethical and regulatory compliance.

Contact Us

Accelerate your bladder cancer therapeutic pipeline with Alfa Cytology's validated T24 Xenograft Model Service. Whether you require a standard efficacy study or a customized orthotopic or metastatic model, our scientific team is ready to design a program aligned with your preclinical objectives. Please reach out to us today via our inquiry form or email to learn more about our T24 Xenograft Model services.

For research use only. Not intended for any clinical use.